Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Orthofix Medical (OFIX) over the last 16 years, with Q3 2025 value amounting to $62.9 million.

  • Orthofix Medical's Cash & Equivalents rose 10915.69% to $62.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.9 million, marking a year-over-year increase of 10915.69%. This contributed to the annual value of $83.2 million for FY2024, which is 15142.11% up from last year.
  • According to the latest figures from Q3 2025, Orthofix Medical's Cash & Equivalents is $62.9 million, which was up 10915.69% from $65.6 million recorded in Q2 2025.
  • Over the past 5 years, Orthofix Medical's Cash & Equivalents peaked at $94.6 million during Q1 2021, and registered a low of $26.4 million during Q2 2024.
  • For the 5-year period, Orthofix Medical's Cash & Equivalents averaged around $57.2 million, with its median value being $58.0 million (2025).
  • As far as peak fluctuations go, Orthofix Medical's Cash & Equivalents crashed by 5374.58% in 2021, and later soared by 15142.11% in 2024.
  • Quarter analysis of 5 years shows Orthofix Medical's Cash & Equivalents stood at $87.8 million in 2021, then tumbled by 42.29% to $50.7 million in 2022, then plummeted by 34.7% to $33.1 million in 2023, then soared by 151.42% to $83.2 million in 2024, then decreased by 24.48% to $62.9 million in 2025.
  • Its Cash & Equivalents stands at $62.9 million for Q3 2025, versus $65.6 million for Q2 2025 and $58.0 million for Q1 2025.